IRF8-expressing TAMs contribute to tumor-reactive cytotoxic T lymphocyte (CTL) exhaustion by presenting tumor antigens and inducing PD-1 expression on CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.